KIRA8 was house-made as previously reported [10 (link)]. Bortezomib (CAS#179324-69-7) was purchased from AdooQ BioScience (Irvine, CA, USA), thapsigargin (CAS#67526-95-8) from Sigma-Aldrich (St. Louis, MO, USA), and nilotinib (CAS#641571-10-0) from MedChemExpress (Monmouth, NJ, USA). Two PERK inhibitors, GSK2606414 (CAS#1337531-89-1) and AMG PERK 44 (AMG; CAS# 1883548-84-2), and dominant Polo-like kinase 2 (PLK2) inhibitor TC-S 7005 (CAS#1082739-92-1) were purchased from TOCRIS Bioscience (Bristol, UK). All reagents were dissolved in dimethyl sulfoxide (DMSO) to a final concentration of 10 mM as a stock solution and stored at −30 °C.
Free full text: Click here